Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-18-005826
Filing Date
2018-05-03
Accepted
2018-05-03 16:01:38
Documents
53
Period of Report
2018-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q adms10q03312018.htm 10-Q 938130
2 admsq110q2018ex311.htm EX-31.1 14264
3 admsq110q2018ex312.htm EX-31.2 14376
4 admsq110q2018ex321.htm EX-32.1 9254
  Complete submission text file 0001628280-18-005826.txt   3790439

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT adms-20180331.xml EX-101.INS 690136
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT adms-20180331.xsd EX-101.SCH 29921
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT adms-20180331_cal.xml EX-101.CAL 50908
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT adms-20180331_def.xml EX-101.DEF 121841
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT adms-20180331_lab.xml EX-101.LAB 375589
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT adms-20180331_pre.xml EX-101.PRE 211835
Mailing Address 1900 POWELL ST., SUITE 750 EMERYVILLE CA 94608
Business Address 1900 POWELL ST., SUITE 750 EMERYVILLE CA 94608 510-450-3554
Adamas Pharmaceuticals Inc (Filer) CIK: 0001328143 (see all company filings)

EIN.: 421560076 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36399 | Film No.: 18803652
SIC: 2834 Pharmaceutical Preparations